These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 12550114)
1. The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma. Chana JS; Grover R; Tulley P; Lohrer H; Sanders R; Grobbelaar AO; Wilson GD Br J Plast Surg; 2002 Dec; 55(8):623-7. PubMed ID: 12550114 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233 [TBL] [Abstract][Full Text] [Related]
3. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637 [TBL] [Abstract][Full Text] [Related]
4. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Ross DA; Wilson GD Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382 [TBL] [Abstract][Full Text] [Related]
5. The clinical significance of c-myc oncogene expression in melanomas of the scalp. Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877 [TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025 [TBL] [Abstract][Full Text] [Related]
7. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891 [TBL] [Abstract][Full Text] [Related]
8. The prognostic importance of c-myc oncogene expression in head and neck melanoma. Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO Ann Plast Surg; 2001 Aug; 47(2):172-7. PubMed ID: 11506326 [TBL] [Abstract][Full Text] [Related]
9. Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma. Husain Z; FitzGerald GB; Wick MM J Invest Dermatol; 1990 Nov; 95(5):571-5. PubMed ID: 2121834 [TBL] [Abstract][Full Text] [Related]
10. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535 [TBL] [Abstract][Full Text] [Related]
11. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447 [TBL] [Abstract][Full Text] [Related]
12. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447 [TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of SK-MEL-30 human melanoma cells by antisense c-myc oligonucleotides delivered by poly(N-isopropylacrylamide)/ poly(ethyleneimine) copolymer. Dinçer S; Oskay EK; Piskin AK; Zeybek ND; Pişkin E J Tissue Eng Regen Med; 2010 Jun; 4(4):284-90. PubMed ID: 19967748 [TBL] [Abstract][Full Text] [Related]
14. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression. Stewart DA; Xu X; Thomas SD; Miller DM Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846 [TBL] [Abstract][Full Text] [Related]
15. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406 [TBL] [Abstract][Full Text] [Related]
16. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138 [TBL] [Abstract][Full Text] [Related]
17. Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation. Stewart DA; Thomas SD; Mayfield CA; Miller DM Nucleic Acids Res; 2001 Oct; 29(19):4052-61. PubMed ID: 11574688 [TBL] [Abstract][Full Text] [Related]
18. Use of oncogene expression as an independent prognostic marker for primary melanoma. Grover R; Pacifico MD; Wilson GD; Sanders R Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057 [TBL] [Abstract][Full Text] [Related]